Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Amgen Inc. is conducting a Phase 2a clinical study titled A Phase 2a, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases. The study aims to evaluate the safety and tolerability of inebilizumab and blinatumomab in adults with active and refractory systemic lupus erythematosus (SLE) with nephritis and rheumatoid arthritis (RA). This research is significant as it explores potential treatments for challenging autoimmune conditions.
The interventions being tested are inebilizumab, administered via intravenous infusion, and blinatumomab, given through subcutaneous injection. Inebilizumab is being tested in different dosages for SLE with nephritis, while blinatumomab is being tested in varying doses for both SLE with nephritis and RA.
The study follows a non-randomized, sequential intervention model with no masking, focusing on treatment as its primary purpose. This design allows for a structured assessment of the drugs’ effects on the participants.
The study began on June 30, 2025, with an estimated start date, and was last updated on June 25, 2025. These dates are crucial as they mark the study’s progression and provide a timeline for potential results and updates.
This clinical study update could influence Amgen’s stock performance positively if the results show promising outcomes, as it may lead to new treatment options in the autoimmune disease market. Investors should also consider the competitive landscape, as advancements in this area could shift market dynamics.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.